The Lancet retracts hydroxychloroquine study following data concerns - Global News | Canada News Media
Connect with us

Health

The Lancet retracts hydroxychloroquine study following data concerns – Global News

Published

 on


One of the world’s most prestigious medical journals, The Lancet, has retracted an influential COVID-19 research paper after three of the paper’s authors said the patient data used for the study could not be independently verified.

The paper, published on May 22, sparked worldwide concern that using the anti-malarial drug hydroxychloroquine on COVID-19 patients may not be safe.


READ MORE:
Hydroxychloroquine doesn’t prevent COVID-19 in people exposed to the virus, study finds

“After publication of our Lancet article, several concerns were raised with respect to the veracity of the data and analysis conducted by Surgisphere Corporation and its founder and our co-author, Sapan Desai, in our publication,” authors Mandeep Mehra, Frank Ruschitzka and Amit Patel said in a statement published by The Lancet, Thursday.

“Our independent peer reviewers informed us that Surgisphere would not transfer the full dataset, client contracts, and the full ISO audit report to their servers for analysis as such transfer would violate client agreements and confidentiality requirements.

Story continues below advertisement

“As such, our reviewers were not able to conduct an independent and private peer review and therefore notified us of their withdrawal from the peer-review process.

“We deeply apologise to you, the editors, and the journal readership for any embarrassment or inconvenience that this may have caused.”

The observational study had found that after reviewing 96,000 COVID-19 patients across six continents, those treated with hydroxychloroquine had a higher risk of heart arrhythmia and death.

[ Sign up for our Health IQ newsletter for the latest coronavirus updates ]

“It caused people to stop what they’re doing (and) delay the high quality science in order to sort out whether this initial paper was accurate or inaccurate” said Derek Exner, Associate Dean of Clinical Trials at the University of Calgary Cummings School of Medicine.


READ MORE:
Medical journal questioning findings of hydroxychloroquine coronavirus study

The World Health Organization immediately suspended the hydroxycholoroquine arm of its international Solidarity trial pending a safety review.

On Wednesday, WHO Director-General Dr. Tedros Adhanom Ghebreyesus announced that review was complete and that trial would be able to resume.

“The Data Safety and Monitoring Committee of the solidarity trial has been reviewing the data. On the basis of the available mortality data, the members of the committee recommended that there are no reasons to modify the trial protocol,” he said.

Story continues below advertisement

“The executive group received this recommendation and endorsed the continuation of all arms of solidarity trial, including hydroxychloroquine.”

Enrollment for The Alberta HOPE COVID-19 trial at the University of Calgary was suspended following The Lancet study publication as well.


READ MORE:
Alberta’s hydroxychloroquine study cleared to resume, but remains on pause

“Our safety committee has reviewed everything and said that look, the trial looks totally safe and there’s no major adverse affects with hydroxychloroquine,” said Dr. Michael Hill, the trial’s co-lead.






1:47
WHO halts hydroxychloroquine clinical trials


WHO halts hydroxychloroquine clinical trials

Still, the delay has been costly for the project.

In the nearly two weeks since the Alberta research was suspended, COVID-19 cases in that province have dropped.  A spokesperson for Alberta Health says the trial might not resume at all.

Story continues below advertisement

“We understand the trial will remain on hold for the next 10 days while the researchers determine whether to suspend for the summer pending (a) fall recurrence of cases or close the trial formally with a plan for data pooling with international collaborators,” said Tom McMillan in an email to Global News.

The coronavirus pandemic has put pressure on scientists to work faster than ever before, but some researchers worry if the cost of speedy science may be too high.

“Of course this pandemic is unfolding at a very rapid pace and the rate of new knowledge is unprecedented and the rate of data sharing is also unprecedented,” said Dr. Isaac Bogoch, an infectious diseases physician at the University of Toronto.

“But it’s also important that you get it right and there’s clearly got to be a balance of speed with accuracy. You can’t compromise accuracy.

“(That would) erode public trust in science, in medicine and in public health and this is time more than ever before where we need public trust in science, medicine and in public health.”

© 2020 Global News, a division of Corus Entertainment Inc.

Let’s block ads! (Why?)



Source link

Continue Reading

Health

Canada to donate up to 200,000 vaccine doses to combat mpox outbreaks in Africa

Published

 on

 

The Canadian government says it will donate up to 200,000 vaccine doses to fight the mpox outbreak in Congo and other African countries.

It says the donated doses of Imvamune will come from Canada’s existing supply and will not affect the country’s preparedness for mpox cases in this country.

Minister of Health Mark Holland says the donation “will help to protect those in the most affected regions of Africa and will help prevent further spread of the virus.”

Dr. Madhukar Pai, Canada research chair in epidemiology and global health, says although the donation is welcome, it is a very small portion of the estimated 10 million vaccine doses needed to control the outbreak.

Vaccine donations from wealthier countries have only recently started arriving in Africa, almost a month after the World Health Organization declared the mpox outbreak a public health emergency of international concern.

A few days after the declaration in August, Global Affairs Canada announced a contribution of $1 million for mpox surveillance, diagnostic tools, research and community awareness in Africa.

On Thursday, the Africa Centres for Disease Control and Prevention said mpox is still on the rise and that testing rates are “insufficient” across the continent.

Jason Kindrachuk, Canada research chair in emerging viruses at the University of Manitoba, said donating vaccines, in addition to supporting surveillance and diagnostic tests, is “massively important.”

But Kindrachuk, who has worked on the ground in Congo during the epidemic, also said that the international response to the mpox outbreak is “better late than never (but) better never late.”

“It would have been fantastic for us globally to not be in this position by having provided doses a much, much longer time prior than when we are,” he said, noting that the outbreak of clade I mpox in Congo started in early 2023.

Clade II mpox, endemic in regions of West Africa, came to the world’s attention even earlier — in 2022 — as that strain of virus spread to other countries, including Canada.

Two doses are recommended for mpox vaccination, so the donation may only benefit 100,000 people, Pai said.

Pai questioned whether Canada is contributing enough, as the federal government hasn’t said what percentage of its mpox vaccine stockpile it is donating.

“Small donations are simply not going to help end this crisis. We need to show greater solidarity and support,” he said in an email.

“That is the biggest lesson from the COVID-19 pandemic — our collective safety is tied with that of other nations.”

This report by The Canadian Press was first published Sept. 13, 2024.

Canadian Press health coverage receives support through a partnership with the Canadian Medical Association. CP is solely responsible for this content.

The Canadian Press. All rights reserved.

Source link

Continue Reading

Health

How many Nova Scotians are on the doctor wait-list? Number hit 160,000 in June

Published

 on

 

HALIFAX – The Nova Scotia government says it could be months before it reveals how many people are on the wait-list for a family doctor.

The head of the province’s health authority told reporters Wednesday that the government won’t release updated data until the 160,000 people who were on the wait-list in June are contacted to verify whether they still need primary care.

Karen Oldfield said Nova Scotia Health is working on validating the primary care wait-list data before posting new numbers, and that work may take a matter of months. The most recent public wait-list figures are from June 1, when 160,234 people, or about 16 per cent of the population, were on it.

“It’s going to take time to make 160,000 calls,” Oldfield said. “We are not talking weeks, we are talking months.”

The interim CEO and president of Nova Scotia Health said people on the list are being asked where they live, whether they still need a family doctor, and to give an update on their health.

A spokesperson with the province’s Health Department says the government and its health authority are “working hard” to turn the wait-list registry into a useful tool, adding that the data will be shared once it is validated.

Nova Scotia’s NDP are calling on Premier Tim Houston to immediately release statistics on how many people are looking for a family doctor. On Tuesday, the NDP introduced a bill that would require the health minister to make the number public every month.

“It is unacceptable for the list to be more than three months out of date,” NDP Leader Claudia Chender said Tuesday.

Chender said releasing this data regularly is vital so Nova Scotians can track the government’s progress on its main 2021 campaign promise: fixing health care.

The number of people in need of a family doctor has more than doubled between the 2021 summer election campaign and June 2024. Since September 2021 about 300 doctors have been added to the provincial health system, the Health Department said.

“We’ll know if Tim Houston is keeping his 2021 election promise to fix health care when Nova Scotians are attached to primary care,” Chender said.

This report by The Canadian Press was first published Sept. 11, 2024.

The Canadian Press. All rights reserved.

Source link

Continue Reading

Health

Newfoundland and Labrador monitoring rise in whooping cough cases: medical officer

Published

 on

 

ST. JOHN’S, N.L. – Newfoundland and Labrador‘s chief medical officer is monitoring the rise of whooping cough infections across the province as cases of the highly contagious disease continue to grow across Canada.

Dr. Janice Fitzgerald says that so far this year, the province has recorded 230 confirmed cases of the vaccine-preventable respiratory tract infection, also known as pertussis.

Late last month, Quebec reported more than 11,000 cases during the same time period, while Ontario counted 470 cases, well above the five-year average of 98. In Quebec, the majority of patients are between the ages of 10 and 14.

Meanwhile, New Brunswick has declared a whooping cough outbreak across the province. A total of 141 cases were reported by last month, exceeding the five-year average of 34.

The disease can lead to severe complications among vulnerable populations including infants, who are at the highest risk of suffering from complications like pneumonia and seizures. Symptoms may start with a runny nose, mild fever and cough, then progress to severe coughing accompanied by a distinctive “whooping” sound during inhalation.

“The public, especially pregnant people and those in close contact with infants, are encouraged to be aware of symptoms related to pertussis and to ensure vaccinations are up to date,” Newfoundland and Labrador’s Health Department said in a statement.

Whooping cough can be treated with antibiotics, but vaccination is the most effective way to control the spread of the disease. As a result, the province has expanded immunization efforts this school year. While booster doses are already offered in Grade 9, the vaccine is now being offered to Grade 8 students as well.

Public health officials say whooping cough is a cyclical disease that increases every two to five or six years.

Meanwhile, New Brunswick’s acting chief medical officer of health expects the current case count to get worse before tapering off.

A rise in whooping cough cases has also been reported in the United States and elsewhere. The Pan American Health Organization issued an alert in July encouraging countries to ramp up their surveillance and vaccination coverage.

This report by The Canadian Press was first published Sept. 10, 2024.

The Canadian Press. All rights reserved.

Source link

Continue Reading

Trending

Exit mobile version